DUBLIN--(BUSINESS WIRE)--Feb. 20, 2014--
Alkermes
plc (NASDAQ: ALKS) will host a conference call at 8:00 a.m. EST
(1:00 p.m. GMT) on Thursday, Feb. 27, 2014, to discuss the company’s
financial results for the three- and nine-month periods ended Dec. 31,
2013, reflecting the company’s transition to a December 31 year-end.
Management will also provide financial expectations for 2014.
The conference call will be webcast on the Investors section of
Alkermes’ website at www.alkermes.com
or may be accessed by dialing +1 888 424 8151 for U.S. callers and +1
847 585 4422 for international callers. The conference call ID number is
6037988.
A replay of the conference call will be available from 10:30 a.m. EST
(3:30 p.m. GMT) on Thursday, Feb. 27, 2014, through 5:00 p.m. EST (10:00
p.m. GMT) on Thursday, March 6, 2014, and may be accessed by visiting
Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1
630 652 3042 for international callers. The replay access code is
6037988.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company
that applies its scientific expertise and proprietary technologies to
develop innovative medicines that improve patient outcomes. The company
has a diversified portfolio of more than 20 commercial drug products and
a substantial clinical pipeline of product candidates that address
central nervous system (CNS) disorders such as addiction, schizophrenia
and depression. Headquartered in Dublin, Ireland, Alkermes plc has an
R&D center in Waltham, Massachusetts; a research and manufacturing
facility in Athlone, Ireland; and manufacturing facilities in
Gainesville, Georgia and Wilmington, Ohio. For more information, please
visit Alkermes’ website at www.alkermes.com.
Source: Alkermes plc
Alkermes
Eva Stroynowski, +1-781-609-6823
Corporate
Communications
